Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report-Reference-Cited by-同舟云学术

Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report

Published:2023-06-06 Issue:3 Volume:4 Page:841-843
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Akagi Yuina¹²,Yamashita Yusuke¹²^ORCID,Kosako Hideki¹,Furuya Yoshiaki¹²,Hosoi Hiroki¹,Mushino Toshiki¹^ORCID,Murata Shogo¹,Nishikawa Akinori¹,Tamura Shinobu¹^ORCID,Nakao Taisei²³,Sonoki Takashi¹^ORCID

Affiliation:

1. Department of Hematology/Oncology Wakayama Medical University Wakayama Japan

2. Department of Hematology Naga Municipal Hospital Wakayama Japan

3. Department of Internal Medicine Naga Municipal Hospital Wakayama Japan

Abstract

AbstractPatients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B‐cell lymphoma‐2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has described its use in patients undergoing dialysis. Herein, we report the effectiveness of combined venetoclax and azacitidine in a 73‐year‐old man with AML undergoing dialysis and who was ineligible for standard therapies. The safety of venetoclax and azacitidine in patients undergoing dialysis has been reported, and their combination may be a feasible option for patients with AML undergoing dialysis.

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.732

Reference15 articles.

1. New strategies to treat AML: novel insights into AML survival pathways and combination therapies

2. How I treat acute myeloid leukemia presenting with preexisting comorbidities

3. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

4. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

5. Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Azacitidine/meropenem/venetoclax;Reactions Weekly;2023-10-07